References
- Cystic Fibrosis Foundation Patient Registry. Annual Data Report.
Bethesda,
Maryland; 2019.
- Sokol RJ, Durie PR. Recommendations for management of liver and
biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation
Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr
1999;28 Suppl 1:S1-13.
- Debray, Dominque, Kelly D, Houwen R, Strandvik B, Colombo C. Best
practice guidance for the diagnosis and management of cystic
fibrosis-associated liver disease. J Cyst Fibros 2011;10 Suppl
2:S29-36.
- Trikafta (elexacaftor/tezacaftor/ivacaftor) [Package Insert].
Boston, MA: Vertex Pharmaceuticals Inc; 2020.
- Middleton PG, Mall MA, Dřevínek P, Lands LC, McKone EF, Polineni D,
Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee
CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F,
Rowe SM, Jain R; VX17-445-102 Study Group.
Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single
Phe508del allele. N Engl J Med. 2019;381(19):1809-1819.
- Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis
E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM,
Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y,
Taylor-Cousar JL, McCoy KS; VX17-445-103 Trial Group. Efficacy and
safety of the elexacaftor plus tezacaftor plus ivacaftor combination
regimen in people with cystic fibrosis homozygous for the F508del
mutation: a double-blind, randomised, phase 3 trial. Lancet.
2019;394(10212):1940-1948.
Table 1. Patient Demographics